Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Petr Sova"'
Autor:
Jarmila Herůdková, Kamil Paruch, Prashant Khirsariya, Karel Souček, Martin Krkoška, Olga Vondálová Blanářová, Petr Sova, Alois Kozubík, Alena Hyršlová Vaculová
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 19, Iss 10, Pp 830-841 (2017)
Although Chk1 kinase inhibitors are currently under clinical investigation as effective cancer cell sensitizers to the cytotoxic effects of numerous chemotherapeutics, there is still a considerable uncertainty regarding their role in modulation of an
Externí odkaz:
https://doaj.org/article/e81b0f5a2c1d4cceb65c2243075f3a24
Autor:
Olga Vondálová Blanářová, Barbora Šafaříková, Jarmila Herůdková, Martin Krkoška, Silvie Tománková, Zuzana Kahounová, Ladislav Anděra, Jan Bouchal, Gvantsa Kharaishvili, Milan Král, Petr Sova, Alois Kozubík, Alena Hyršlová Vaculová
Publikováno v:
PLoS ONE, Vol 12, Iss 11, p e0188584 (2017)
Searching for new strategies for effective elimination of human prostate cancer cells, we investigated the cooperative cytotoxic action of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and two platinum-based complexes, cisplatin or
Externí odkaz:
https://doaj.org/article/f28d4460e94e49e89d81127c542aa443
Autor:
Jarmila Lauková, Alois Kozubík, Jiřina Hofmanová, Jana Nekvindová, Petr Sova, Mary Pat Moyer, Jiří Ehrmann, Alena Hyršlová Vaculová
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0141020 (2015)
We demonstrated for the first time an outstanding ability of rosiglitazone to mediate a profound enhancement of LA-12-induced apoptosis associated with activation of mitochondrial pathway in human colon cancer cells. This effect was preferentially ob
Externí odkaz:
https://doaj.org/article/e9e52676bb104a499fa76dc88f32d583
Publikováno v:
Pharmaceutical development and technology. 26(1)
The pharmaceutical industry has to tackle the explosion of high amounts of poorly soluble APIs. This phenomenon leads to numerous sophisticated solutions. These include the use of multifactorial data analysis identifying correlations between the comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::435b84194dbabad6e112f0dc7e9d1fcd
https://pubmed.ncbi.nlm.nih.gov/33121318
https://pubmed.ncbi.nlm.nih.gov/33121318
Autor:
Petr Sova, PrashantKumar Khirsariya, Jarmila Herůdková, Kamil Paruch, Alois Kozubík, Olga Vondálová Blanářová, Alena Hyršlová Vaculová, Karel Souček, Martin Krkoška
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 19, Iss 10, Pp 830-841 (2017)
Neoplasia (New York, N.Y.)
Neoplasia (New York, N.Y.)
Although Chk1 kinase inhibitors are currently under clinical investigation as effective cancer cell sensitizers to the cytotoxic effects of numerous chemotherapeutics, there is still a considerable uncertainty regarding their role in modulation of an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8e55b88e6b3d0b4832521ac44105099
http://www.sciencedirect.com/science/article/pii/S1476558617302452
http://www.sciencedirect.com/science/article/pii/S1476558617302452
Autor:
Ladislav Anděra, Alena Hyršlová Vaculová, Silvie Tománková, Jan Bouchal, Milan Král, Martin Krkoška, Petr Sova, Zuzana Kahounová, Barbora Šafaříková, Gvantsa Kharaishvili, Alois Kozubík, Olga Vondálová Blanářová, Jarmila Herůdková
Publikováno v:
PLoS ONE
PLoS ONE, Vol 12, Iss 11, p e0188584 (2017)
PLoS ONE, Vol 12, Iss 11, p e0188584 (2017)
Searching for new strategies for effective elimination of human prostate cancer cells, we investigated the cooperative cytotoxic action of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and two platinum-based complexes, cisplatin or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da7094c999dd6f2ba2345d9077e957ed
http://europepmc.org/articles/PMC5705153
http://europepmc.org/articles/PMC5705153
Autor:
Jiřina Hofmanová, Iva Jelínková, Alois Kozubík, A. Hyršlová Vaculová, Petr Sova, O. Vondálová Blanářová
Publikováno v:
Cell Proliferation. 46:665-676
OBJECTIVES: Therapeutic potential of conventionally used platinum‐based drugs in treatment of colorectal tumours has been limited due to high incidence of tumour resistance to them and to their severe side effects. This evokes a search for more sui
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93c6858ecb4c096e786c49dccc3610e7
https://doi.org/10.1111/cpr.12061
https://doi.org/10.1111/cpr.12061
Autor:
János Szöllősi, Viktor Horváth, Jiřina Hofmanová, Alois Kozubík, Ladislav Anděra, Alena Hyršlová Vaculová, György Vereb, Petr Sova, Olga Vondálová Blanářová, Karel Souček, Árpád Szöőr, Belma Skender, Iva Jelínková
Publikováno v:
Carcinogenesis. 32:42-51
TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) can selectively trigger apoptosis in various cancer cell types. However, many cancer cells are resistant to death receptor-mediated apoptosis. Combination therapy with platinum complexes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc9772ac1b9e185905d52b996ed6aa3f
https://doi.org/10.1093/carcin/bgq220
https://doi.org/10.1093/carcin/bgq220
Autor:
Petr Müller, Veronika Kvardová, Eva Roubalová, Petr Sova, Eva Michalová, Bořivoj Vojtěšek, Šárka Bořilová, Lenka Zdražilová Dubská, Roman Hrstka
Publikováno v:
Investigational New Drugs. 28:445-453
In this study, we characterized the effects of LA-12 on tumor cell lines possessing wild type p53 and on p53-deficient/mutant cell lines and the results were compared to those obtained using cisplatin. We have determined changes of p53 levels, of its
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::379979571d7c3979ba4d47bb436b09ab
https://doi.org/10.1007/s10637-009-9270-4
https://doi.org/10.1007/s10637-009-9270-4
Autor:
Eva Roubalová, Veronika Kvardová, Karima Bourougaa, Robin Fåhraeus, Darren J. Powell, Roman Hrstka, Petr Sova, Borivoj Vojtesek, Frantisek Zak, Marco M. Candeias
Publikováno v:
Anti-Cancer Drugs. 19:369-379
The platinum(II)-based complex cisplatin is one of the most frequently used antitumour agents; however, a high incidence of harmful side effects and the frequent emergence of acquired resistance are the major clinical problems. The novel platinum(IV)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97068a16827d4eedee6458a94d62cab4
https://doi.org/10.1097/cad.0b013e3282f7f500
https://doi.org/10.1097/cad.0b013e3282f7f500